By Professor Michael Leonard Friedlander

Journal articles

Alsop K; Fereday S; Meldrum C; DeFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G, 2012, 'BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group', Journal of Clinical Oncology, 30, pp. 2654 - 2663, http://dx.doi.org/10.1200/JCO.2011.39.8545

Kirchhoff T; Offit K; Gaudet MM; Pharoah PDP; Easton DF; Antoniou AC; Mcguffog L; Humphreys MK; Dunning AM; Bojesen SE; Nordestgaard BG; Flyger H; Kang D; Yoo KY; Noh DY; Ahn SH; Dork T; Schürmann P; Karstens JH; Hillemanns P; Couch FJ; Olson J; Vachon C; Wang X; Cox A; Brock I; Elliott G; Reed MWR; Burwinkel B; Meindl A; Brauch H; Justenhoven C; Hamann U; Ko YD; Fischer HP; Brüning T; Pesch B; Harth V; Rabstein S; Broeks A; Schmidt MK; Van 't Veer LJ; Braaf LM; Johnson N; Fletcher O; Gibson L; Peto J; Turnbull C; Seal S; Renwick A; Rahman N; Wu PE; Yu JC; Hsiung CN; Shen CY; Southey MC; Hopper JL; Hammet F; van Dorpe T; Dieudonne AS; Hatse S; Lambrechts D; Andrulis IL; Bogdanova N; Antonenkova N; Rogov JI; Prokofieva D; Bermisheva M; Khusnutdinova E; van Asperen CJ; Tollenaar RAEM; Hooning MJ; Devilee P; Margolin S; Lindblom A; Milne RL; Arias JI; Pilar Zamora M; Benítez J; Severi G; Baglietto L; Giles GG; Chenevix-Trench G; Spurdle AB; Beesley J; Chen X; Holland H; Healey S; Wang-Gohrke S; Chang-Claude J; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Agnarsson BA; Caligo MA; Godwin AK; Nevanlinna H; Heikkinen T; Fredericksen Z, 2012, 'Breast cancer risk and 6q22.33: Combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2', Plos One, 7, http://dx.doi.org/10.1371/journal.pone.0035706

Mileshkin LR; Narayan K; Moore KN; Rischin D; Trimble EL; Stockler MR; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Shrivastava SK; Small W; Thomas G; Craighead PS; Gebski V, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', Journal of Clinical Oncology, 30, pp. TPS5116 - TPS5116, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5116

Grimison PS; Chatfield MD; Mazhar D; Toner GC; Chester JD; Stockler MR; Stark DP; Thomson DB; Shamash J; Friedlander M; White J; Gebski V; Wason J; Boland AL; Rimmer YL; McDonald A; Gurney H; Rosenthal M; Singhal N; Williams MV, 2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.', Journal of Clinical Oncology, 30, pp. 4531 - 4531, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4531

Oza AM; Cibula D; Oaknin A; Poole CJ; Mathijssen RHJ; Sonke GS; Colombo N; Špacek J; Vuylsteke P; Hirte HW; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Tchakov I; Friedlander M, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', Journal of Clinical Oncology, 30, pp. 5001 - 5001, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5001

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044

Sjoquist KM; Lee C; Lord S; Chatfield MD; Friedlander M; Simes J; Marschner I, 2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', Journal of Clinical Oncology, 30, pp. 5081 - 5081, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5081

Molife LR; Mateo J; McGoldrick T; Krebs M; Drew Y; Banerjee SN; Nicum S; Ranson M; Rustin GJS; Sessa C; Plummer R; Leunen K; Friedlander M; Swaisland H; Burke W; McCormack P; Pemberton K; Tchakov I; Kaye SB; Gourley C, 2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.', Journal of Clinical Oncology, 30, pp. 3048 - 3048, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3048

Ang JE; Gourley C; High HA; Shapira-Frommer R; Powell CB; Castonguay V; De Greve J; Yap TA; Fong PCC; Olmos D; Banerjee SN; Chen L-M; Friedlander M; Kaufman B; Oza AM; De Bono JS; Gore ME; Kaye SB, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.', Journal of Clinical Oncology, 30, pp. 5022 - 5022, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5022

Ribi K; Aldridge J; Phillips K-A; Thompson A; Harvey V; Thuerlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J, 2012, 'Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer', BRITISH JOURNAL OF CANCER, 106, pp. 1618 - 1625, http://dx.doi.org/10.1038/bjc.2012.156

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2012, 'Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer', New England Journal of Medicine, 366, pp. 1382 - 1392, http://dx.doi.org/10.1056/NEJMoa1105535

Friedlander M, 2012, 'A century of cosmic rays', NATURE, 483, pp. 400 - 401, http://dx.doi.org/10.1038/483400a

Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B, 2012, 'Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer', Journal of Clinical Oncology, 30, pp. 372 - 379, http://dx.doi.org/10.1200/JCO.2011.36.9215

Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA, 2012, 'Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study', Journal of Clinical Oncology, 30, pp. 19 - 26, http://dx.doi.org/10.1200/JCO.2010.33.0068

Berek JS; Crum C; Friedlander M, 2012, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 119, pp. S118 - S129, http://dx.doi.org/10.1016/S0020-7292(12)60025-3

Phillips KA; Milne RL; Rookus MA; Goldgar D; Friedlander M; McLachlan SA; Buys S; Antoniou AC; Birch K; Terry MB; Easton DF; Weideman P; Daly M; Andrieu N; John EM; Hooning MJ; Andrulis IL; Caldes T; Olsson H; Hopper JL, 2012, 'Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 10, pp. A11 - A11, http://dx.doi.org/10.1186/1897-4287-10-s2-a11

Goldstein D; Bennett BK; Webber K; Boyle F; De Souza P; Wilcken NRC; Scott E; Toppler R; Murie P; O''Malley L; Mccourt J; Friedlander M; Hickie IB; Lloyd AR, 2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148

Watts KJ; Meiser B; Mitchell GF; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson MA; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K; TFGT CG; Parasyn A; Andrews L, 2012, 'How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer', BMC Cancer, 12, pp. 320, http://dx.doi.org/10.1186/1471-2407-12-320

Cowin PA; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz VA; Friedlander M; McNally O; Quinn MA; Campbell P; Defazio A; Bowtell DDL; George J, 2012, 'LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin', Cancer Research, 72, pp. 4060 - 4073, http://dx.doi.org/10.1158/0008-5472.CAN-12-0203

Bonolis L; Friedlander M, 2012, 'Massimilla Baldo Ceolin Obituary', PHYSICS TODAY, 65, pp. 60 - 60, http://dx.doi.org/10.1063/PT.3.1686

High H; Friedlander M, 2012, 'Pathological diagnosis of ovarian cancer', Hereditary Cancer in Clinical Practice, 10, pp. A82 - A82, http://dx.doi.org/10.1186/1897-4287-10-s2-a82

Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Staehle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MKB; Oza AM, 2011, 'A Phase 3 Trial of Bevacizumab in Ovarian Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 365, pp. 2484 - 2496, http://dx.doi.org/10.1056/NEJMoa1103799

Cruz-Rivera E; Friedlander M, 2011, 'Feeding preferences of mesograzers on aquacultured Gracilaria and sympatric algae', AQUACULTURE, 322, pp. 218 - 222, http://dx.doi.org/10.1016/j.aquaculture.2011.09.035

Sjoquist KM; Martyn J; Edmondson RJ; Friedlander ML, 2011, 'The role of hormonal therapy in gynecological cancers - Current status and future directions', International Journal of Gynecological Cancer, 21, pp. 1328 - 1333, http://dx.doi.org/10.1097/IGC.0b013e31821d6021

Griffiths G, 2011, 'International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial', JOURNAL OF CLINICAL ONCOLOGY, 29, pp. 2171 - 2177, http://dx.doi.org/10.1200/JCO.2010.32.3139

Grimison PS; Thomson DB; Stockler MR; Chatfield MD; Friedlander M; Gebski V; Boland AL; Houghton BB; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2011, 'Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial.', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4561

Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533

Juraskova I; Jarvis S; Mok K; Peate M; Meiser B; Mireskandari S; Friedlander M, 2011, 'OVERcome: An intervention study to improve sexual function in women with breast cancer.', J Clin Oncol, 29, pp. 9066, http://www.ncbi.nlm.nih.gov/pubmed/28021576

Helland A; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DDL, 2011, 'Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers', Plos One, 6, http://dx.doi.org/10.1371/journal.pone.0018064

Bowtell DDL; Friedlander M; Quinn M; Mitchell G, 2011, 'A response to the forgotten fallopian tube', Nature Reviews Cancer, 11, pp. c2, http://dx.doi.org/10.1038/nrc2946-c2

Lee CK; Hudson M; Coates A; Ackland S; Gebski V; Lord S; Friedlander M; Boyle F; Simes RJ, 2011, 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129, pp. 467 - 476, http://dx.doi.org/10.1007/s10549-011-1471-9

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care', Oncology Nursing Forum, 38, pp. 627 - 631

Kiely B; Friedlander M; Milne RL; Stanhope L; Russell P; Jenkins MA; Weideman P; McLachlan S; Grant PT, 2011, 'Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.', Familial Cancer, 10, pp. 505 - 514

Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Lang I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thuerlimann B, 2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up', LANCET ONCOLOGY, 12, pp. 1101 - 1108, http://dx.doi.org/10.1016/S1470-2045(11)70270-4

Collinson I; Roberts-Thomson R; Faulkner D; Rischin D; Friedlander M; Mileshkin L, 2011, 'Carboplatin dosing in ovarian cancer: problems and pitfalls.', International Journal of Gynecological Cancer, 21, pp. 1213 - 1218

Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-lauraine E; Lord S; Simes RJ; Friedlander M, 2011, 'Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer', British Journal of Cancer, 105, pp. 360 - 365

Bae S; Friedlander M; Scott C, 2011, 'CART-WHEEL.org can facilitate research into rare gynecological tumors.', International Journal of Gynecological Cancer, 21, pp. 1517 - 1519

Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh M; Loman N; Scott C; Friedlander M; kaufman B; Garber J; Tutt A; Robson ME, 2011, 'Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.', Journal of CLIN ONCOL, 29, pp. 4224 - 4226

Friedlander M; Trimble E; Tinker A; Alberts D; Avall-lundqvist E; Brady M; Harter P; Pignata S; Pujade-lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland LM; Glasspool R; Gonzalez-martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GW, 2011, 'Clinical trials in recurrent ovarian cancer.', International Journal of Gynecological Cancer, 21, pp. 771 - 775

Rustin G; Vergote I; Eisenhauer E; Pujade-lauraine E; Quinn M; Thigpen T; Du bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J, 2011, 'Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 Agreed by the gynecological cancer intergroup (GCIG)', International Journal of Gynecological Cancer, 21, pp. 419 - 423

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'Development and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', Oncology Nursing Forum, 38, pp. 627 - 631

Peate ML; Meiser B; Hickey MS; Thewes B; Saunders C; Butow PN; Martinello R; Martinello R; Fallon-Ferguson J; Wakefield C; Zorbas H; Rovelli S; Friedlander ML, 2011, 'Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer', The breast journal, 17, pp. 112 - 114, http://dx.doi.org/10.1111/j.1524-4741.2010.01033.x

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Lee CK; Friedlander M; Brown C; Gebski V; Georgoulopoulos A; Vergote I; Pignata S; Donadello N; Schmalfeldt B; Delva R; Mirza MQ; Sauthier P; Pujade-lauraine E; Lord SJ; Simes RJ, 2011, 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.', Journal of the National Cancer Institute, 103, pp. 1338 - 1342

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2011, 'Early Progressive and Sustained Dysfunction of Sensory Axons Underlies Paclitaxel-induced Neuropathy', Muscle and Nerve, 43, pp. 367 - 374, http://dx.doi.org/10.1002/mus.21874

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548

Regan MM; Price KN; Giobbie-Hurder A; Thuerlimann B; Gelber RD, 2011, 'Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer', BREAST CANCER RESEARCH, 13, http://dx.doi.org/10.1186/bcr2837

Peate M; Meiser B; Friedlander M; Zorbas H; Rovelli S; Sansom-daly U; Sangster J; Hadzi-Pavlovic D; Hickey MS, 2011, 'It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer. An Australian Fertility Decision Aid Collaborative Group Study.', Journal of Clinical Oncology, 29, pp. 1670 - 1677

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Back to profile page